Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Issue 13 (24th March 2015)

• Record Type: Journal Article
• Authors: Hariri, Susan; Bennett, Nancy M.; Niccolai, Linda M.; Schafer, Sean; Park, Ina U.; Bloch, Karen C.; Unger, Elizabeth R.; Whitney, Erin; Julian, Pamela; Scahill, Mary W.; Abdullah, Nasreen; Levine, Diane; Johnson, Michelle L.; Steinau, Martin; Markowitz, Lauri E.; the HPV-IMPACT Working Group, 1
• Is Part Of: Vaccine. Volume 33:Issue 13(2015)
• Page Start: 1608
• Page End: 1613
• Publication Date: 2015-03-24
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.01.084
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Background</title> <p id="spar0005">Prevention of pre-invasive cervical lesions is an important benefit of HPV vaccines, but demonstrating impact on these lesions is impeded by changes in cervical cancer screening. Monitoring vaccine-types associated with lesions can help distinguish vaccine impact from screening effects. We examined trends in prevalence of HPV 16/18 types detected in cervical intraepithelial neoplasia 2, 3, and adenocarcinoma in situ (CIN2+) among women diagnosed with CIN2+ from 2008 to 2012 by vaccination status. We estimated vaccine effectiveness against HPV 16/18-attributable CIN2+ among women who received ≥1 dose by increasing time intervals between date of first vaccination and the screening test that led to detection of CIN2+ lesion.</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">Data are from a population-based sentinel surveillance system to monitor HPV vaccine impact on type-specific CIN2+ among adult female residents of five catchment areas in California, Connecticut, New York, Oregon, and Tennessee. Vaccination and cervical cancer screening information was retrieved. Archived diagnostic specimens were obtained from reporting laboratories for HPV DNA typing.</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">From 2008 to 2012, prevalence of HPV 16/18 in CIN2+ lesions statistically significantly decreased from 53.6% to 28.4% among women who received at least one dose (<italic>P</italic><sub>trend</sub> < .001) but not among unvaccinated women (57.1% vs 52.5%; <italic>P</italic><sub>trend</sub> = .08) or women with unknown vaccination status (55.0% vs 50.5%; <italic>P</italic><sub>trend</sub> = .71). Estimated vaccine effectiveness for prevention of HPV 16/18-attributable CIN2+ was 21% (95% CI: 1–37), 49% (95% CI: 28–64), and 72% (95% CI: 45–86) in women who initiated vaccination 25–36 months, 37–48 months, and >48 months prior to the screening test that led to CIN2+ diagnosis.</p> </sec> <sec> <title id="sect0025">Conclusions</title> <p id="spar0020">Population-based data from the United States indicate significant reductions in CIN2+ lesions attributable to types targeted by the vaccines and increasing HPV vaccine effectiveness with increasing interval between first vaccination and earliest detection of cervical disease.</p> </sec> </abstract>